Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap

Autor:	Joseph Emil Amegadzie, John-Michael Gamble, Jamie Farrell, Zhiwei Gao
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Asthma β2-adrenergic agonists COPD Nested case–control Diseases of the respiratory system RC705-779
Zdroj:	Respiratory Research, Vol 23, Iss 1, Pp 1-9 (2022)
Druh dokumentu:	article
ISSN:	1465-993X
DOI:	10.1186/s12931-022-02295-0
Popis:	Abstract β2-agonists provide necessary bronchodilatory action, are recommended by existing clinical practice guidelines and are widely prescribed for patients with these conditions. We examined the risk of all-cause mortality and hospitalization for pneumonia associated with long-or short-acting β2-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA use. In a nested case–control of 185,407 patients, we found no association between β2-agonist use and the risk of pneumonia in patients with asthma, COPD, or asthma-COPD overlap. In contrast, new SABA [HR 1.82 (95% CI 1.04–3.20)] or LABA [HR 2.77 (95% CI 1.22–6.31)] use was associated with an increased risk of all-cause mortality compared to ICS use in COPD patients.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/930e31c85c474016be3f92357e6ae11d Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.